In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA nephropathy (IgAN).The $65-per-share deal is due to close within the next three months, said Vertex, which plans to fund the acquisition with cash in […]
